InvestorsHub Logo
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 2410

Monday, 05/08/2023 4:20:30 PM

Monday, May 08, 2023 4:20:30 PM

Post# of 2958
ENTA FY2Q23* financials—3/31/23_pro_forma_ cash=$454M† :

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-35

FY2Q23 royalty revenue was $18.7M.

FY2Q23 R&D expenses were $43.5M, somewhat below the run rate for ENTA’s FY2023 guidance of $210-230M.

FY2Q23 SG&A expenses were $13.8M, slightly above the run rate for ENTA’s FY2023 guidance of $46-52M.

†Including $200M from partial monetization of Mavyret royalties and a $28.7M tax refund due from IRS.

*ENTA’s fiscal years end on September 30.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News